NEUCORE BIO, INC.

Biotech · Private

Extracellular vesicle (EV)-based gene therapy for CMT1A using engineered nanoparticles to deliver therapeutic RNA/DNA/proteins to Schwann cells

Grants
$655K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Fibroblast-Derived Engineered Extracellular Vesicles (eEVs) as New Nucleic Acid Therapeutic Delivery Systems for Peripheral Nervous System (PNS) Genetic Disorders$304,951
Federal grantDepartment of Health and Human Services · Phase I · Fibroblast-derived Engineered Extracellular Vesicle (FieEV) Technology for Targeted Delivery of RNA Therapeutics to treat CMT1A Diseases$350,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2871REDVAULT BIOSCIENCES LP——
2872Vertex Pharmaceuticals——
2873Q-State Biosciences, Inc.——
2874NEUCORE BIO, INC.——
2875PROMILEAD, LLC——
2876LIBREDE——
2877DELINEATE INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.